Intelligent Bio Solutions announced that on February 27, 2023, the Company received a notification from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). As a result, the Company is now in compliance with the Minimum Bid Price Requirement for continued listing and Nasdaq considers the matter closed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on INBS:
- Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement
- Intelligent Bio files FDA 513 submission for fingerprinting drug screening
- Intelligent Bio Solutions Inc. files FDA 513(g) regulatory submission for Intelligent Fingerprinting Drug Screening Cartridge
- Intelligent Bio Solutions reports Q2 EPS (46c) vs ($4.65) last year
- Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights